Patents by Inventor J. J. Wright
J. J. Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8211896Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: GrantFiled: October 1, 2010Date of Patent: July 3, 2012Assignee: Chemocentryx, Inc.Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell
-
Publication number: 20120014997Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Inventors: Solomon Ungashe, J.J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
-
Publication number: 20110257183Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: ApplicationFiled: April 22, 2011Publication date: October 20, 2011Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Premack, Thomas Schall
-
Publication number: 20110021523Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: October 1, 2010Publication date: January 27, 2011Applicant: CHEMOCENTRYX, INC.Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
-
Publication number: 20100227902Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: ApplicationFiled: May 14, 2010Publication date: September 9, 2010Applicant: CHEMOCENTRYX, INC.Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 7649011Abstract: Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.Type: GrantFiled: December 22, 2003Date of Patent: January 19, 2010Assignee: Chemocentryx, Inc.Inventors: Anita Melikian, Jennifer Burns, Brian E. McMaster, Thomas Schall, J. J. Wright
-
Publication number: 20090270616Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 7, 2009Publication date: October 29, 2009Applicant: CHEMOCENTRYX, INCInventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
-
Publication number: 20090163498Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: June 11, 2008Publication date: June 25, 2009Applicant: CHEMOCENTRYX, INC.Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
-
Publication number: 20090118307Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: October 15, 2008Publication date: May 7, 2009Applicant: CHEMOCENTRYX, INC.Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
-
Publication number: 20080293717Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 2, 2008Publication date: November 27, 2008Applicant: CHEMOCENTRYX, INC.Inventors: SOLOMON UGASHE, Zheng Wei, J.J. Wright, Andrew Pennell
-
Publication number: 20080261966Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: ApplicationFiled: February 1, 2008Publication date: October 23, 2008Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 7420055Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: GrantFiled: May 13, 2004Date of Patent: September 2, 2008Assignee: Chemocentryx, Inc.Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
-
Publication number: 20070203131Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: ApplicationFiled: April 23, 2007Publication date: August 30, 2007Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 7227035Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: GrantFiled: May 19, 2004Date of Patent: June 5, 2007Assignee: ChemocentryxInventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 7101894Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: wherein Ar is a substituted or unsubstituted 5–14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; R1 is selected from the group consisting of substituted or unsubstituted aryl(C1–C4)alkyl, heteroaryl(C1–C4)alkyl, —C(O)R11, and —C(O)NR11R12, wherein each R11 and R12 independently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C1–C4)alkyl, substituted or unsubstituted (C4–C8)cycloalkyl(C1–C4)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C1–C4)alkyl and substituted or unsubstituted hetero(C4–C8)cycloalkyl(C1–C4)alkyl; R2 is H or (C1–C8)alkyl; and ZN is a substituted or unsubstituted hetero(C6–C10)bicycloalkyl group.Type: GrantFiled: August 29, 2002Date of Patent: September 5, 2006Assignee: ChemoCentryx, Inc.Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
-
Publication number: 20060106218Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: December 8, 2004Publication date: May 18, 2006Applicant: ChemoCentryx, Inc.Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
-
Publication number: 20060074121Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.Type: ApplicationFiled: September 1, 2005Publication date: April 6, 2006Applicant: ChemoCentryx, Inc.Inventors: Wei Chen, Penglie Zhang, James Aggen, Daniel Dairaghi, Andrew Pennell, Subhabrata Sen, J.J. Wright
-
Publication number: 20050256130Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: November 1, 2004Publication date: November 17, 2005Applicant: ChemoCentryx, Inc.Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
-
Publication number: 20050234034Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.Type: ApplicationFiled: March 2, 2005Publication date: October 20, 2005Applicant: ChemoCentryx, Inc.Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Wei Chen, Daniel Dairaghi, Penglie Zhang
-
Publication number: 20050165067Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: January 27, 2005Publication date: July 28, 2005Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell